Commentary|Videos|June 19, 2026

Compounding, Peptides, and GLP-1s: Opportunities & Risks for Pharmacies in 2026

Name: Compounding, Peptides, and GLP-1s: Opportunities & Risks for Pharmacies in 2026
Uploaded: 2026-06-19T13:52:46.737Z
Duration: 49 min 1 s
Description: Compounding, Peptides, and GLP-1s: Opportunities & Risks for Pharmacies in 2026

Author(s)Brian Nowosielski, Dae Lee, PharmD, Esq, CPBS , Lucas Morgan, Esq

Lucas Morgan, Esq, and Dae Lee, PharmD, Esq, CPBS, present on the significant opportunities and regulatory risks surrounding compounded peptides and GLP-1 products in 2026.

With the shortage of commercially available drugs creating a massive opening for independent pharmacies to diversify their portfolios and tap into cash-based revenue, this growth is met with intense scrutiny from the FDA and state boards of pharmacy. This is especially prominent in the glucagon-like peptide-1 (GLP-1) and compounded peptide spaces.